CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
对健康组织反应性的风险：新型 CAR 需检测被忽视的结合特性
英文原题：The risk of reactivity against healthy tissues: Novel CARs demand testing for overlooked binding properties.
查看英文原题
The risk of reactivity against healthy tissues: Novel CARs demand testing for overlooked binding properties.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
越来越多的嵌合抗原受体（CAR）正被转化为用于恶性和自身免疫性疾病的细胞疗法。虽然针对癌细胞选择性CAR的靶向设计正在持续改进，但对被忽视的健康组织识别的特异性检测通常并未开展，这可能低估了CAR-T 细胞应用时严重组织损伤的风险。以设计用于靶向慢性淋巴细胞白血病细胞的Fc R/IgM受体/FAIM3/TOSO特异性CAR为例，我们展示了一种用于发现对健康组织反应性的筛选方案，并讨论了此类临床前检测在提高CAR-T 细胞应用安全性方面的价值。
展开英文摘要原文
A rapidly growing number of chimeric antigen receptors (CARs) is being translated into cell therapy for malignant and autoimmune diseases. While cancer cell-selective CAR targeting is undergoing continuous refinement, specific testing for overlooked recognition of healthy tissues is commonly not performed, which potentially results in underestimating of the risk of severe tissue damage upon CAR T cell application.
Using the Fc R/IgM receptor/FAIM3/TOSO-specific CAR, designed to target chronic lymphocytic leukemia cells, we exemplarily outline a screen to uncover reactivities to healthy tissues and discuss the value of such pre-clinical testing to improve safety in CAR T cell application.
论文信息
- 作者
- Holzinger A、Weber F、Abken H
- 第一作者单位
- Leibniz Institute for Immunotherapy (LIT), Division of Genetic Immunotherapy, Regensburg, Germany.Germany
- 通讯作者单位
- Leibniz Institute for Immunotherapy (LIT), Division of Genetic Immunotherapy, Regensburg, Germany. Electronic address: hinrich.abken@ukr.de.Germany
- 期刊
- Molecular therapy : the journal of the American Society of Gene Therapy2025 Jun 4
- 原文标识
- PubMed 39818204 · DOI 10.1016/j.ymthe.2024.12.035
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →